Oruka Therapeutics Insider Paul Quinlan Sells Shares

Paul Quinlan, the General Counsel of Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 733 shares of the company on June 15, 2026. The shares were sold at an average price of $69.69, totaling $51,082.77. This transaction was not part of a pre-planned trading program.

What Changed in Paul Quinlan's Oruka Therapeutics Position

Paul Quinlan reduced his holdings in Oruka Therapeutics by 733 shares, a move that reflects a decrease in his personal stake in the company. This sale was executed at an average price of $69.69 per share, bringing the total value of the transaction to $51,082.77.

Other Institutional Activity in Oruka Therapeutics

Several institutional investors have also been active in Oruka Therapeutics. FMR LLC increased its holdings by 170,019 shares, bringing its total to 7,431,403 shares valued at approximately $364.51 million. Paradigm Biocapital Advisors LP made a significant addition of 610,000 shares, ending with 2,320,316 shares worth about $113.81 million. Meanwhile, BlackRock, Inc. reduced its position by 12,328 shares, holding 3,527,087 shares valued at $173.00 million.

Oruka Therapeutics Stock Snapshot

Shares of Oruka Therapeutics traded near $69.89. The company has a market cap of $4.22 billion and a forward P/E ratio indicating it isn't profitable. The stock has seen a 52-week low of $10.77 and a high of $91.00. Its 50-day moving average is $63.70, while the 200-day moving average is $37.60. Oruka maintains a strong liquidity position with a current ratio of 23.76 and a quick ratio of 23.38.

Recent Earnings

Oruka Therapeutics has been operating at a loss, with an EPS of -$1.93 and a net margin of 0. The company's return on equity is negative at -27.31%. The next earnings report is scheduled for August 10, 2026.

Insider Buying and Selling at Oruka Therapeutics, Inc.

On June 15, 2026, several insiders engaged in transactions. Joana Goncalves, the Chief Medical Officer, bought 7,000 shares at $7.32 and sold 3,500 shares. Laura Lee Sandler, Chief Operating Officer, sold 600 shares at $69.69. Arjun Agarwal, Senior Vice President of Finance, sold 395 shares under a planned transaction.

Analysts Set New Price Targets

On May 14, 2026, BTIG reiterated its buy rating with a $151 price target for Oruka Therapeutics. Earlier, HC Wainwright & Co. and UBS maintained buy ratings with price targets of $120 and $100, respectively. The consensus among analysts is a strong buy, with a mean price target of $142.17 based on 12 opinions.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. It focuses on developing innovative antibody therapies for psoriasis and other inflammatory conditions. The company is led by CEO Dr. Lawrence Otto Klein and employs 68 people. Oruka's lead products include ORKA-001, targeting interleukin-23, and ORKA-002, targeting interleukin-17A and 17F, both in phase 2 trials.

Bottom Line

Paul Quinlan's recent sale of shares in Oruka Therapeutics is a notable insider transaction. Investors often track such moves for insights into executive perspectives on the company's prospects. It's important to remember that 13F filings and insider transactions reflect past actions and may not indicate current positions or future intentions.